Updating results

213 results

Sort: Relevance | Date

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Tivozanib for treating advanced renal cell carcinoma (TA512)

Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published March 2018

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019

Nusinersen for treating spinal muscular atrophy (TA588)

Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults

Technology appraisal guidance Published July 2019

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Technology appraisal guidance Published June 2019

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Technology appraisal guidance Published June 2019

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous NSCLC

Technology appraisal guidance Published June 2019

Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults

Technology appraisal guidance Published March 2019

Cochlear implants for children and adults with severe to profound deafness (TA566)

Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness

Technology appraisal guidance Published March 2019

Benralizumab for treating severe eosinophilic asthma (TA565)

Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults

Technology appraisal guidance Published March 2019 Last updated September 2019

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

Technology appraisal guidance Published February 2019

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Technology appraisal guidance Published February 2019

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published February 2019

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence

Technology appraisal guidance Published February 2019

Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

Technology appraisal guidance Published January 2019

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung

Technology appraisal guidance Published January 2019

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

Technology appraisal guidance Published January 2019

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib

Technology appraisal guidance Published January 2019

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Evidence-based recommendation on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage III melanoma with lymph node involvement in adults

Technology appraisal guidance Published December 2018

Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)

Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published December 2018

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults

Technology appraisal guidance Published March 2018

Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee (TA508)

Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects

Technology appraisal guidance Published March 2018

Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published February 2018

Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

Evidence-based recommendations on lesinurad (Zurampic) for treating chronic hyperuricaemia (too much uric acid/urate in blood) in adults with gout

Technology appraisal guidance Published February 2018

Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

Evidence-based recommendations on ixazomib (Ninlaro) with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Technology appraisal guidance Published February 2018

Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF) in adults

Technology appraisal guidance Published February 2018

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

Technology appraisal guidance Published January 2018

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma (MCL) in adults

Technology appraisal guidance Published January 2018

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer

Technology appraisal guidance Published January 2018

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2018

Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2018

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published January 2018

Golimumab for treating non-radiographic axial spondyloarthritis (TA497)

Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults

Technology appraisal guidance Published January 2018

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to

Technology appraisal guidance Published November 2019

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to

Technology appraisal guidance Published November 2019

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Technology appraisal guidance Published November 2019

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

Technology appraisal guidance Published October 2019

Idelalisib for treating refractory follicular lymphoma (TA604)

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults

Technology appraisal guidance Published October 2019

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019